Back to Authors

Abdalla, Hesham M

Mayo Clinic

Department of Internal Medicine, Mayo Clinic, Phoenix, AZ 85054, USA.

Citations 2

Comparing Early Intervention to Watchful Waiting: A Review on Risk Stratification and Management in Asymptomatic Aortic Stenosis
Khedr, Ahmed E. , Odeh, Nour B., Bcharah, George , Abdalla, Hesham, Senjab, Abdulrahman , Zeineddine, Rawan M. , Ram, Jai, Farina, Juan M. , Crystal, Owen , Barrus, Bryan , Lester, Steven J., Shipman, Justin , Alsidawi, Said , Sell‐Dottin, Kristen , Arsanjani, Reza , Abdalla, Hesham M, Ram, Jaikrishnan, Crystal, Owen R, Sell-Dottin, Kristen A , Arsanjani, Reza , Farina, Juan M , Alsidawi, Said , Khedr, Ahmed , Ram, Jaikrishnan

Medicina | March 4, 2025 | Volume: 61 | Issue: 3 | Pages: 448

10.3390/medicina61030448 Get It

Aortic stenosis is a progressive condition with substantial implications for morbidity and mortality. In recent years, attention has shifted toward risk stratification and the development of individualized management plans to optimize treatment outcomes. The management of asymptomatic patients has become a topic of significant controversy, as emerging studies challenge traditional watchful waiting guidelines and propose the potential benefits of early intervention. While early intervention may reduce overall morbidity and mortality in this patient population, the associated procedural risks remain a critical consideration. This review seeks to analyze the existing literature, offering an updated perspective on patient risk stratification and evidence evaluating both management approaches.
Lipoprotein (a) as a Cardiovascular Risk Factor in Controversial Clinical Scenarios: A Narrative Review
Abdalla, Hesham, Mahmoud, Ahmed , Khedr, Ahmed E. , Farina, Juan M. , Scalia, Isabel G. , Abbas, Mohammed Tiseer , Awad, Kamal A., Ali, Nima Baba , Bismee, Nadera N. , Esfahani, Sogol Attaripour , Javadi, Niloofar , Pereyra, Milagros , Alsidawi, Said , Lester, Steven J., Ayoub, Chadi , Arsanjani, Reza , Abdalla, Hesham M, Mahmoud, Ahmed K , Baba Ali, Nima , Attaripour Esfahani, Sogol, Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Alsidawi, Said , Scalia, Isabel G , Abbas, Mohammed Tiseer

International Journal of Molecular Sciences | October 14, 2024 | Volume: 25 | Issue: 20 | Pages: 11029

10.3390/ijms252011029 Get It

Lipoprotein (a) is a complex lipid molecule that has sparked immense interest in recent years, after studies demonstrated its significant association with several cardiovascular conditions. Lp(a) promotes cardiovascular disease through its combined proatherogenic, pro-inflammatory, and prothrombotic effects. While the measurement of Lp(a) has become widely available, effective methods to reduce its concentration are currently limited. However, emerging data from ongoing clinical trials involving antisense oligonucleotides have indicated promising outcomes in effectively reducing Lp(a) concentrations. This may serve as a potential therapeutic target in the management and prevention of myocardial infarction, calcific aortic stenosis, and cerebrovascular accidents. In contrast, the role of Lp(a) in atrial fibrillation, in-stent restenosis, cardiac allograft vasculopathy, and bioprosthetic aortic valve degeneration remains unclear. This review article aims to thoroughly review the existing literature and provide an updated overview of the evidence surrounding the association of Lp(a) and these cardiovascular diseases. We seek to highlight controversies in the existing literature and offer directions for future investigations to better understand Lp(a)’s precise role in these conditions, while providing a summary of its unique molecular characteristics.